Abstract
Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1.
Original language | English |
---|---|
Pages (from-to) | S815 |
Journal | Journal of Thoracic Oncology |
Volume | 13 |
Issue number | 10 |
DOIs | |
Publication status | Published - 22 Oct 2018 |